MedPath

Influence of Sedentary Time on Skeletal Muscle Protein Metabolism

Not Applicable
Completed
Conditions
Sedentary Lifestyle
Interventions
Behavioral: 7 days of habitual physical activity followed by 7 days of reduced physical activity
Registration Number
NCT02624011
Lead Sponsor
University of Birmingham
Brief Summary

This study will investigate the influence of increased sedentary time on long-term measures of muscle protein synthesis and metabolic health. The investigators will test the hypothesis that increased time spent in sedentary behaviours will lead to a reduction in long-term measures of muscle protein synthesis and compromised metabolic health.

Detailed Description

Sarcopenia, the loss of muscle mass with age, is thought to be accelerated by an inactive, sedentary lifestyle. Increased sedentary time has consistently been associated with lower muscle mass and compromised metabolic health. However, there is currently a lack of direct evidence to support these associations.

Therefore, this study will investigate whether increased sedentary time (reduced step count and exercise cessation) directly influences long-term measures of muscle protein synthesis and metabolic health in young, active adults. Following a 7 day period of normal habitual physical activity, participants will undertake a 7 day period of step reduction and exercise cessation. It is hypothesised that 7 days of increased sedentary time will result in a reduction in long-term rates of muscle protein synthesis and a worsening of metabolic health.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
8
Inclusion Criteria
  • Body mass index (18.5-29.99 kg/m2)
  • Active - defined as: ≥ 7000 steps per day (assessed during screening) and taking part in regular exercise (defined as participation in ≥ 3 sessions of aerobic and/or resistance exercise type sessions a week for ≥ 6 months prior to recruitment)
  • Good general health
Exclusion Criteria
  • Lidocaine allergy
  • Hypertension (≥140/90 mmHg)
  • Current participation in another clinical study
  • Previous participation in this study
  • Bleeding disorder/s
  • Current or recent smoker
  • Past history of substance abuse and/or taking prescription or non-prescription medication (e.g., beta-blockers, insulin or thyroxine) or supplements that may influence normal metabolic responses.
  • Participants who have previously (within 5 years of the present study) had 4 or more muscle biopsies obtained from the thigh quadriceps region will be ineligible.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Physical inactivity7 days of habitual physical activity followed by 7 days of reduced physical activityStudy arm consisting of 7 days of habitual physical activity followed by 7 days of step reduction and exercise cessation.
Primary Outcome Measures
NameTimeMethod
Muscle protein synthesis (FSR %/day)0-14 days

Long-term muscle protein synthesis (FSR %/day) will be determined using deuterium oxide (D2O) to compare muscle protein synthesis rates over the first 7 day period and the second 7 day period.

Secondary Outcome Measures
NameTimeMethod
Rate of fat oxidation at rest (g/min)For 20 minutes at day 7 and day 14

Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) at rest will be measured using indirect calorimetry to calculate the rate of fat oxidation at rest (g/min).

Rate of fat oxidation during an oral glucose tolerance test (g/min)At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14

Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) following an oral glucose drink will be measured using indirect calorimetry to calculate the rate of fat oxidation during an oral glucose tolerance test (g/min).

Blood glucose concentrationAt 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14

Blood glucose concentration will be assessed in blood samples taken during the oral glucose tolerance test.

Blood insulin concentrationAt 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14

Blood insulin concentration will be assessed in blood samples taken during the oral glucose tolerance test.

Rate of carbohydrate oxidation during an oral glucose tolerance test (g/min)At 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14

Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) following an oral glucose drink will be measured using indirect calorimetry to calculate the rate of carbohydrate oxidation during an oral glucose tolerance test (g/min).

Blood fatty acid concentrationAt 0, 30, 60, 90 and 120min of the oral glucose tolerance test at day 7 and day 14

Blood fatty acid concentration will be assessed in blood samples taken during the oral glucose tolerance test.

Rate of carbohydrate oxidation at rest (g/min)For 20 minutes at day 7 and day 14

Whole body oxygen consumption (VO2, L/min) and carbon dioxide production (VCO2, L/min) at rest will be measured using indirect calorimetry to calculate the rate of carbohydrate oxidation at rest (g/min).

Trial Locations

Locations (1)

School of Sport Exercise and Rehabilitation Sciences, University of Birmingham

🇬🇧

Birmingham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath